Trials / Completed
CompletedNCT04784533
A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
A Study to Evaluate Maintenance of Hair Regrowth Following Dose Reduction of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 317 (actual)
- Sponsor
- Concert Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CTP-543 | Oral dosing |
| DRUG | Placebo | Oral dosing |
Timeline
- Start date
- 2021-02-26
- Primary completion
- 2023-05-16
- Completion
- 2023-05-16
- First posted
- 2021-03-05
- Last updated
- 2024-10-09
- Results posted
- 2024-10-09
Locations
39 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04784533. Inclusion in this directory is not an endorsement.